TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04146051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Descartes-08
Description: Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA
Study: NCT02043171

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A Placebo comparator

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A Placebo comparator
Study: NCT02359032

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets
Study: NCT02598141

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological sampling grinding
Description: One half of the biological material collected during the intervetion (according to standard procedures) will be ground using the Ultra Turrax technique before proceeding with culturing.
Study: NCT02043171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMB plus Vitamin D
Description: Active comparator of HMB (3 g/d) plus Vitamin D (2,000 IU/d)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMB plus Vitamin D
Description: Active comparator of HMB (3 g/d) plus Vitamin D (2,000 IU/d)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Exercise
Description: This group will not participate in 3 times per week strength training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-Exercise
Description: This group will not participate in 3 times per week strength training
Study: NCT02598141

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological sampling with standard procedures
Description: One half of the biological material collected during the intervetion (according to standard procedures) will be treated according to standard techniques before proceeding with culturing.
Study: NCT02043171

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: This group will participate in a supervised 3 times per week strength training program

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: This group will participate in a supervised 3 times per week strength training program
Study: NCT04638933

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01550289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: NaCl 0.9% solution
Description: 0.5 ml, Subcutaneous
Study: NCT03267706

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palliative Care Comprehensive Tool
Description: Clinicians assigned to the newly developed Palliative Care Comprehensive Tool will be trained during a 1 hour period on the application of the tool; Including rationale for tool development, objective of the tool and demonstration of the tool in action
Study: NCT03090802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentoring Adolescent Mothers at School (MAMAS)
Description: Through the MAMAS program, 12 older mentor mothers, who themselves were pregnant adolescents, will mentor 240 younger adolescent mothers to provide ongoing psychosocial support, navigate re-admission to school, and facilitate access to an existing State-sponsored cash transfer, the child support grant (CSG), in the early postpartum period.
Study: NCT01897844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2984 (100, 2000, 3000 mcg bid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2984 (100, 2000, 3000 mcg bid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2984 (100, 2000, 3000 mcg bid)
Study: NCT04146051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Descartes-08
Description: Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Descartes-08
Description: Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA
Study: NCT04578119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sliding Intubating Technique
Description: Sliding technique' means that endotracheal intubation is performed by sliding the videolayngoscope blade under the epiglottis smoothly.
Study: NCT01797445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E/C/F/TDF
Description: 150/150/200/300 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TDF Placebo
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E/C/F/TAF Placebo
Description: Tablet administered orally once daily
Study: NCT01897844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00933192

Intervention type: DEVICE
Intervention: Siemens Acuson Antares ultrasound
Description: skeletal muscle ultrasound of the musculus quadriceps, on two different days, two observers

Intervention type: DEVICE
Intervention: Siemens Acuson Antares ultrasound
Description: skeletal muscle ultrasound of the musculus quadriceps, on two different days, two observers
Study: NCT01897844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01933061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane 150- mg/m² IV on Days 1, 8, and 15 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane 150 mg/m\^2 intravenously on Days 1, 8, and 15 of a 28-day cycle
Study: NCT01721343

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assessment of therapy complications
Description: Undergo enhanced usual care with an RCM and PCM
Study: NCT00254657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Started with one 500 mg tablet/day and titrated upward as tolerated over 6 weeks by 500 mg/week to a maximum dose of 3000 mg/day.
Study: NCT00994162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EZCare/V1STA Negative Pressure Wound Therapy System
Description: Vacuum Source and dressing kit that generates negative pressure over the wound.
Study: NCT00606528

Intervention type: OTHER
Intervention: No intervention
Description: None. This is an observational study.
Study: NCT02091947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FMS (Magstim rapid2)
Description: 5 Hz FMS, over bilateral sacral roots.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: FMS (Magstim rapid2)
Description: 5 Hz FMS, over bilateral sacral roots.
Study: NCT00139841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine HCl
Description: Dose of 120 mg/m2 on Day 1 and Day 2 of each treatment cycle (every 21 days). Patients who are continuing to experience clinical benefit at Cycle 6, as assessed by the investigator, may receive up to 2 additional cycles, to a maximum of 8 cycles.
Study: NCT04090983

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy (Hesslinger protocol)
Description: Cognitive-behavioral therapy in a group format focusing on improving symptoms of ADHD, specifically by using skills in counteracting hyperactivity and impulsiveness, and promoting mindful awareness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CADDI protocol)
Description: Cognitive-behavioral therapy in a group format focusing on improving inattentive symptoms of ADHD, specifically by using skills in organizing, executing, and completing activity, and promoting mindful awareness.
Study: NCT01142193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USL255

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00616291

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine
Study: NCT00832312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ozone-oxygen mixture
Description: 10 cc of an ozone-oxygen mixture with ozone concentration 10000 mcg/L (10 mcg/ml)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo (saline)
Description: Injection of 1cc of saline into the knee joint
Study: NCT04690712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: All students who attended the school were provided training by the researchers to improve oral and dental health and general hygiene. These trainings were made using slide shows and various entertaining materials. In addition, education was transformed into a drama with a theater show, and the importance of hand washing, hair and toilet hygiene was explained.~In addition to hygiene, students were given training on correct eating patterns for a day so that they could develop healthy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: All students who attended the school were provided training by the researchers to improve oral and dental health and general hygiene. These trainings were made using slide shows and various entertaining materials. In addition, education was transformed into a drama with a theater show, and the importance of hand washing, hair and toilet hygiene was explained.~In addition to hygiene, students were given training on correct eating patterns for a day so that they could develop healthy.
Study: NCT00254657

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04093752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC
Study: NCT02621697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive motor training
Description: Initially an intervention consisting of double duty activities (motor-cognitive) and the control group will be subjected to a conventional treatment based on stretching and strengthening will be held.
Study: NCT01381406

Intervention type: DRUG
Intervention: TIO
Description: Patients receiving tiotropium bromide at index within the study period.

Intervention type: DRUG
Intervention: TIO+FSC
Description: Patients receiving tiotropium bromide plus fluticasone propionate-salmeterol xinafoate combination at time of index within the study period.
Study: NCT02621697

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesiotherapeutic conventional treatment
Description: Standardized global stretching and strengthening with squat exercise, plantar flexion in foot and elbow flexion supporting body weight in the hands arranged on the wall
Study: NCT02818335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414 Reference Fasted
Description: Administered Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414 Test Fasted
Description: Administered Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414 Test Fed
Description: Administered Orally
Study: NCT03485950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefepime
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin-Tazobactam
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazobactam
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazobactam
Description: Given IV
Study: NCT02929147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours. In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours. In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen
Description: The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: In the Group 3 the PCA will contain placebo.
Study: NCT02808923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam Rolling
Description: Participants will perform unilateral hamstring rolling for 2 repetitions of 1 minute with 15 second rest breaks on each leg with a 6x 36 foam roller.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching
Description: Participants will perform supine static hamstring stretch on a wall for 2 repetitions of 1 minute with 15 second rest breaks on each leg. When the position no longer causes a moderate stretching sensation to the hamstring, subjects will move their bodies closer to the wall to intensify the stretch.
Study: NCT03475069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Custom Designed Exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plates Exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calisthenics Exercises
Study: NCT02448355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT swept source DRI-Atlantis, Topcon
Description: 3-dimensional scanning protocol with 3 μm axial resolution and a speed of 100,000 A-scans per second. 256 B-scans to be taken on an area of 12 × 9 μm.
Study: NCT04156334

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction of teeth in general anaesthesia using either computer-controlled intraosseous anesthesia device or carpule for local anaesthesia
Description: QuickSleeper 5 with DHT needles or carpule with periapical/nerve block needles will be used to administer local anaesthetic before teeth extraction in general anaesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction of teeth in general anaesthesia using either computer-controlled intraosseous anesthesia device or carpule for local anaesthesia
Description: QuickSleeper 5 with DHT needles or carpule with periapical/nerve block needles will be used to administer local anaesthetic before teeth extraction in general anaesthesia.
Study: NCT01537094

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C 250 mg once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C 1,000 mg once daily
Study: NCT03341234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 30 ml %0,25 bupivacaine
Study: NCT00619944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumefantrine - lopinavir/ritonavir drug interaction
Description: Lumefantrine 480 mg co-formulated with artemether 80 mg administered as single dose to HIV-positive adults receiving lopinavir/ritonavir 400 mg/100 mg twice daily
Study: NCT03341234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: 2 ml saline subcutaneously

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound guided block
Study: NCT00619944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumefantrine only arm
Description: Lumefantrine 480 mg co-formulated with artemether 80 mg administered as a single dose to antiretroviral naive HIV-positive patients
Study: NCT04481607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3454
Description: TQB3454 tablets is a small molecule oral drug.
Study: NCT03341234

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound guided block
Study: NCT01510834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multibehavioral, Computerized Tailored Intervention STR2IVE
Description: All participants were provided with the same multibehavioral CTI system and chose two or three behavior programs to complete (smoking cessation, stress management, and/or depression prevention)monthly. They were asked to complete an assessments at baseline, 30-days, and 90-days. They were allowed to access the system workbook anytime but they must wait a minimum of 25 days between assessments and programs at time points 1 and 2, and 55 days between time points 2 and 3.
Study: NCT04501835

Intervention type: OTHER
Intervention: Diagnostic and treatment evaluation
Description: No intervention, description of the diagnostic evaluation and the treatment
Study: NCT02584777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: QD (Once a day)
Study: NCT01268033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: two infusions - at the dose of 375 mg/m²- will be administered at one week of interval

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two infusions - at the dose of 375 mg/m² - will be administrered at one week of interval
Study: NCT00912340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study: NCT00820144

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTB by nasal way

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: absorption of CTB by oral way
Description: absorption of CTB by oral way

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: absorption of dukoral by oral way
Description: absorption of dukoral by oral way

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: absorption of CTB by sublingual way
Description: absorption of CTB by sublingual way
Study: NCT00334646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral GW679769
Description: 150mg oral, once daily on days 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Cyclophosphamide 500-700mg/m2
Description: IV Cyclophosphamide 500-700mg/m2 on day 1 of each cycle
Study: NCT02532426

Intervention type: PROCEDURE
Intervention: Muscle biopsy
Description: The biopsy is performed on the vastus lateralis muscle at rest and 2 hours after an acute exercise, with a local anesthesia.

Intervention type: PROCEDURE
Intervention: Muscle biopsy
Description: The biopsy is performed on the vastus lateralis muscle at rest and 2 hours after an acute exercise, with a local anesthesia.
Study: NCT04254796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training for Awareness, Resilience, and Action (TARA)
Description: This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
Study: NCT01779596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00397878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00657722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Angiography and Computed Tomography
Description: Preoperative angiography and Computed Tomography
Study: NCT03842215

Intervention type: DEVICE
Intervention: smart physical exam
Description: Use smart physical exam to collect functional performance
Study: NCT03644108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucinex® ER 600 mg
Description: Single dose of Mucinex® 600 mg ER Bi-Layer tablet
Study: NCT00192595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)
Study: NCT03870009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ARDS patients
Description: The patient will be installed on the scanner bed. Two series of tomographic sections will be acquired: one during an expiratory break, the other during an inspiratory pause.~cyclic hyperinflation measured by semi-automatic segmentation and by manual segmentation
Study: NCT03004976

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood
Description: Umbilical cord blood will be infused intravenously through a peripheral IV line after premedication with diphenhydramine, hydrocortisone, and acetaminophen. Units will be from a public cord blood bank with selection based on blood type, race, and the number of cells in the pre cryopreservation product, targeting a dose range of 0.5 to 5 x 10\^7 TNCC/kg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product will be acellular and will consist of tissue culture medium 199 (TC-199 \[pink\]) with 1% dimethyl sulfoxide (DMSO), which are standard components in cellular products. The volume of placebo product will be 50 mL, which is in the range of a typical UCB unit that has been washed and thawed after cryopreservation. Infusion and premedication procedures will be the same as those conducted for the umbilical cord blood arm.
Study: NCT01933321

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intrathecal autologous stem cell
Description: Mobilization and collection of stem cells for intravenous and intrathecal administration